Navigation Links
Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Date:2/11/2008

.

In addition, Pharmacopeia announced that enrollment in its ongoing Phase 2a PS433540 (DARA) clinical trial in subjects with Stage I and Stage II hypertension is progressing well. The trial remains on schedule with results expected in the second quarter of 2008.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically validated mechanisms of action in a single compound. There is considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

About Pharmacopeia

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications

Pharmacopeia, Inc.

609-452-3643

'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
2. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Third Quarter 2007 Financial Results
4. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
7. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
11. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Established and new medical technology service ... penetrate the growing Eastern European medical devices market. ... team and regional/local offices, reducing the costs incurred ... crucial advantage as medical technology service providers are ... New analysis from Frost & Sullivan, Medical Technologies ...
(Date:9/30/2014)... , Sept. 30, 2014 CytRx ... research and development company specializing in oncology, today ... clinical trial evaluating aldoxorubicin compared to topotecan in ... who have relapsed or were refractory to prior ... widely-used chemotherapeutic agent, doxorubicin. CytRx has received Orphan ...
(Date:9/29/2014)...  Repeated exposure to broad-spectrum antibiotics in the first ... obesity, say researchers from The Children,s Hospital of ... on data from electronic health records from the extensive ... that children with four or more exposures to broad ... be at risk for obesity. The study, published online ...
Breaking Medicine Technology:Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 2Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... reach USD 8,020.1 million by 2020, according to ... Growing demand for personalized medicine and theranostics, and ... are expected to be key factors driving market ... growing global base of geriatric population and chronic ...
(Date:9/30/2014)... During this online virtual event, ... health including achieving hormonal balance, relieving menopause symptoms, ... , The details of the ... 6-9, 2014, Location: Online Event, Registration: Complimentary , ... , Monday, October 6th, Steven F. Hotze, M.D., ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... Washington, DC (PRWEB) September ... **MEDIA ADVISORY** , ... Contact:    Anne Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Give Hope® Celebration , ... , Address:    The Army and ...
(Date:9/30/2014)... York (PRWEB) September 30, 2014 ... of Hudson Allergy , will discuss how restaurants ... allergies and other special dietary restrictions at the ... & Food Service Professionals, October 21 in New York ... this incredibly important topic to such an engaged industry ...
Breaking Medicine News(10 mins):Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... how we put the brakes on a racing heartbeat. ... Chicago explain in the May 11 issue of Circulation Research ... the rapid beating of the heart's "fight-or-flight" reaction to adrenaline. ... is responsible for setting the pace of the beating heart, ...
... The central government is aiming for 100 percent registration of ... Death Act 1969 that would simplify the process, an ... serious issue as this helps in maintaining a record for ... the birth registration record is 64 percent as some of ...
... 100 percent registration of births by 2010 by amending the ... simplify the process, an official said Friday. ,'Registration ... maintaining a record for a person for his or her ... percent as some of the states have still not implemented ...
... a single sphere in the US they would like to ... is the cooked chickens market. ,The U.S. ... to familiarize the U.S. market with its cooked chickens." ... about such common practices among Chinese farmers, like flooding crops ...
... of motor disorders: stiffness, slowness, tremors, difficulties walking and ... other symptoms with narcolepsy, a sleep disorder characterized by ... and general sleep disorder. ,Now a team ... why the two disorders share something in common: ...
... receiver Robert Sillen, hired to improve healthcare for state ... his jurisdiction. ,According to Sillen the 50-page ... and protect California communities from diseases carried by inmates ... says, taxpayers will get more for their dollar from ...
Cached Medicine News:Health News:Slowing the Racing Heart 2Health News:Government to Amend Birth Registration Act 2Health News:Government to Amend Birth Registration Act 2Health News:China Eyeing US Cooked Chickens Market 2Health News:UCLA Researchers Discover Link Between Parkinsons and Narcolepsy 2Health News:Brickbats And Bouquets For U.S Prison Healthcare In-Charge 2Health News:Brickbats And Bouquets For U.S Prison Healthcare In-Charge 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: